Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer

Lancet

Volumn 350, Issue 9079, 1997, Pages 681-686

  Lévi, Francis ^a,b   Zidani, Rachid ^a   Misset, Jean Louis ^a  

^a International Organization for Cancer Chronotherapy

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INFUSION SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL TIME; TREATMENT FAILURE; VOMITING;

EID: 0041055512     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03358-8     Document Type: Article

References (28)

1. Lévi F. Chronopharmacology of anticancer agents. In: Redfern PH, Lemmer B, eds. Handbook of experimental pharmacology: physiology and pharmacology of biological rhythms - cancer chemotherapy. Berlin: Springer-Verlag, 1997: 299-331.
2. Smaaland R, Laerum OD, Lote K, et al. DNA synthesis in human bone marrow is circadian stage dependent. Blood 1991; 77: 2603-11.
3. Smaaland R, Abrahamsen JF, Svardal AM, et al. DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer 1992; 66: 39-45.
4. Harris B, Song R, Soong S, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197-201.
5. Boughattas N, Lévi F, Fournier C, et al. Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane (trans-1) oxalatoplatinum (II) in mice. Cancer Res 1989; 49: 3362-68.
6. Metzger G, Massari C, Etienne MC, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients. Clin Pharmacol Ther 1994; 56: 190-201.
7. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, USA: JB Lippincott, 1993: 929-77.
8. Piedbois P. Advanced colorectal cancer meta-analysis project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer -evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
9. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose-intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14: 3-11.
10. Poon M, O'Conell M, Moertel G, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-17.
11. Scheithauer W, Rosen H, Kornek GB, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-55.
12. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver mtastases. Lancet 1994; 344: 1255-60.
13. Lévi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29(9): 1280-84.
14. Machover D, Diaz-Rubio E, De Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-98.
15. Lévi F. Chronotherapy for gastrointestinal cancers. Curr Opin Oncol 1996; 8: 334-41.
16. Caussanel JP, Lévi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046-50.
17. Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump: high antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893-900.
18. Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer mtastases: a randomized multiinstitutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
19. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
20. Leichman CG, Fleming TR, Muggia FM. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-11.
21. Hansen RM, Ryan L, Anderson T, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996; 88: 668-74.
22. Hill M, Norman A, Cunningham D, et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival and quality of life in advanced colorectal cancer. J Clin Oncol 1995; 13: 2317-23.
23. Bertheault-Cvitko vie F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14(11): 2950-58.
24. Lévi F, Dogliotti L, Perpoint B, et al. A multicentre phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with previously untreated metastatic colorectal cancer (MCC): Proceedings of 33rd Annual Meeting of American Society of Clinical Oncology, May 17-20, 1997. Denver, CO, USA; #945 (abstr).
25. Glimelius B, Huffman K, Graf W, Pahlman L, Sjoden PO, for the Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
26. Buyse M, Molenberghs G. Criteria for the validation of surrogate end-points in randomized experiments. Biometrics (in press).
27. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver mtastases. Lancet 1994; 343: 1405-10.
28. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224(4): 509-22.